Jazz Pharmaceuticals plc
Research Jazz Pharmaceuticals plc (JAZZ) on Bullrun: market cap USD 14.92B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerJAZZ
- ExchangeNASDAQ
- CountryIreland
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 14.92B
- Financial periodFY2025
- RevenueUSD 4.27B
- Revenue growth4.9%
- Net income-USD 356.15M
- Free cash flowUSD 1.30B
Valuation Snapshot
latest market cap is USD 14.92B.
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma;
Frequently asked questions
What is Jazz Pharmaceuticals plc's market cap?
Jazz Pharmaceuticals plc's market capitalization is USD 14.92B.
What does Jazz Pharmaceuticals plc do?
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH);